Trial intelligence / Profile preview

OBINUSS – Obinutuzumab in diffuse systemic sclerosis

2025-524003-68-00Phase 2Authorised

Sponsor: Assistance publique - Hôpitaux de Paris
Start: Jul 2026
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing Obinutuzumab (Gazyvaro) with Placebo (NaCl 0.9%) (2 arms). Planned start Jul 2026; status: authorised.

Drugs

obinutuzumab

Conditions

systemic sclerosis (SSc)

Beyond the preview

Go deeper on 2025-524003-68-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-524003-68-00.